Literature DB >> 7115339

Interaction of ligands with cytochrome P-450. On the 442 nm spectral species generated during the oxidative metabolism of pyridine.

P Hlavica, J Mietaschk, I Baden.   

Abstract

When added to aerobic rabbit liver microsomal fractions fortified with an NADPH-generating system, pyridine initially produces a type II difference spectrum such as is observed with other aromatic amines. There is a time-dependent conversion of this perturbation into a new spectral species characterized by an absorbance maximum at 442 nm and a minor peak at 389 nm. Experiments with inhibitors of the cytochrome P-450-dependent electron-transport chain suggest that these species originate from binding to the haemoprotein of metabolic intermediate(s) derived from the amine substrate. Analysis of the incubation mixtures by t.l.c., high-pressure liquid chromatography, u.v.- and mass-spectrometry reveals the presence of a single metabolite arising from cytochrome P-450-catalysed oxidation of the heteroaromatic tertiary amine, which was identified as pyridine N-oxide, obviously accounting for adduct formation. This view is supported by comparative studies on the spectral changes generated by exogenous amine oxide with NADPH-reduced cytochrome P-450. Moreover, dithiothreitol, a potent N-oxidase inhibitor, strongly suppresses development of the 442 nm and 389 nm complexes. The ability of forming low-spin adducts with ferrous cytochrome P-450 absorbing around 440 nm appears to be an inherent property of different types of N-oxides. Considering the dipole character of the N+-O- function, a co-ordinate iron-oxygen bond is proposed to be formed in these complexes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7115339      PMCID: PMC1158368          DOI: 10.1042/bj2040425

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  33 in total

1.  Reconstituted liver microsomal enzyme system that hydroxylates drugs, other foreign compounds, and endogenous substrates. IX. The formation of a 455-nm metabolite-cytochrome P-450 complex.

Authors:  J C Kawalek; W Levin; D Ryan; A Y Lu
Journal:  Drug Metab Dispos       Date:  1976 Mar-Apr       Impact factor: 3.922

2.  ON THE ROLE OF UBIQUINONE IN MITOCHONDRIA. SPECTROPHOTOMETRIC AND CHEMICAL MEASUREMENTS OF ITS REDOX REACTIONS.

Authors:  L SZARKOWSKA; M KLINGENBERG
Journal:  Biochem Z       Date:  1963

3.  Heterogeneity of liver microsomal cytochrome P-450: the spectral characterization of reactants with reduced cytochrome P-450.

Authors:  J Werringloer; R W Estabrook
Journal:  Arch Biochem Biophys       Date:  1975-03       Impact factor: 4.013

4.  Nitric oxide complexes of cytochrome P-450.

Authors:  R E Ebel; D H O'Keefe; J A Peterson
Journal:  FEBS Lett       Date:  1975-07-15       Impact factor: 4.124

5.  Studies on P-450. VI. The spin state of P-450 solubilized from bovine adrenocortical mitochondria.

Authors:  F Mitani; S Horie
Journal:  J Biochem       Date:  1969-08       Impact factor: 3.387

6.  The preparation of microsomes.

Authors:  R von Jagow; H Kampffmeyer; M Kiese
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1965-06-01

7.  The influence of methyl substitution on the N-demethylation and N-oxidation of normethadone in animal species.

Authors:  A H Beckett; M Mitchand; A A Shihab
Journal:  J Pharm Pharmacol       Date:  1971-12       Impact factor: 3.765

Review 8.  Binding of nitrogen containing compounds to microsomal cytochromes.

Authors:  D J Temple
Journal:  Xenobiotica       Date:  1971 Jul-Oct       Impact factor: 1.908

9.  The influence of cytochrome P-450 induction on the metabolic formation of 455-NM complexes from amphetamines.

Authors:  M R Franklin
Journal:  Drug Metab Dispos       Date:  1974 May-Jun       Impact factor: 3.922

10.  The conversion of pyrrolizidine alkaloids to N-oxides and to dihydropyrrolizine derivatives by rat-liver microsomes in vitro.

Authors:  A R Mattocks; I N White
Journal:  Chem Biol Interact       Date:  1971-10       Impact factor: 5.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.